Corbus Pharmaceuticals, Inc.
Records under this name other than the patents Corbus Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 5 of 5 · Back to Corbus Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,085,964 | Ultrapure TETRAHYDROCANNABINOL-11-OIC Acids Lapsed on the fee record Ended Oct 2, 2026 · Medium confidence | Lapsed on the fee record | Ended Oct 2, 2026 | Medium confidence |
| US 8,637,087 | Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids Term ended Term ended Dec 13, 2025 · From the USPTO record | Term ended | Term ended Dec 13, 2025 | From the USPTO record |
| US 9,820,964 | Ultrapure TETRAHYDROCANNABINOL-11-OIC Acids Formerly held Lapsed on the fee record Ended Nov 21, 2025 · Medium confidence | Lapsed on the fee record | Ended Nov 21, 2025 | Medium confidence |
| US 9,801,849 | Ultrapure TETRAHYDROCANNABINOL-11-OIC Acids Lapsed on the fee record Ended Oct 31, 2025 · Medium confidence | Lapsed on the fee record | Ended Oct 31, 2025 | Medium confidence |
| US 11,052,066 | Ultrapure TETRAHYDROCANNABINOL-11-OIC Acids Formerly held Lapsed on the fee record Ended Jul 6, 2025 · Medium confidence | Lapsed on the fee record | Ended Jul 6, 2025 | Medium confidence |